EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS

Brendan P Lucey iD, Haiyan Liu, Cristina D Toedebusch, David Freund, Tiara Redrick, Samir L Chahin, Kwasi G Mawuenyega, James G Bollinger, Vitaliy Ovod iD, Nicolas R Barthélemy, Randall J Bateman

Annals of Neurology · 2023-07 · 94 (1) · 27-40

DOI: 10.1002/ana.26641 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Neurology, online erschienen am 20.04.2023. Verfasst von Brendan P Lucey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, BrightFocus Foundation, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In Alzheimer's disease, hyperphosphorylated tau is associated with formation of insoluble paired helical filaments that aggregate as neurofibrillary tau tangles and are associated with neuronal loss and cognitive symptoms. Dual orexin receptor antagonists decrease soluble amyloid‐β levels and amyloid plaques in mouse models overexpressing amyloid‐β, but have not been reported to affect tau phosphorylation. In this randomized controlled trial, we tested the acute effect of suvorexant, a dual orexin receptor antagonist, on amyloid‐β, tau, and phospho‐tau.

Methods

Thirty‐eight cognitively unimpaired participants aged 45 to 65 years were randomized to placebo (N = 13), suvorexant 10 mg (N = 13), and suvorexant 20 mg (N = 12). Six milliliters of cerebrospinal fluid were collected via an indwelling lumbar catheter every 2 hours for 36 hours starting at 20:00. Participants received placebo or suvorexant at 21:00. All samples were processed and measured for multiple forms of amyloid‐β, tau, and phospho‐tau via immunoprecipitation and liquid chromatography‐mass spectrometry.

Results

The ratio of phosphorylated‐tau‐threonine‐181 to unphosphorylated‐tau‐threonine‐181, a measure of phosphorylation at this tau phosphosite, decreased ~10% to 15% in participants treated with suvorexant 20 mg compared to placebo. However, phosphorylation at tau‐serine‐202 and tau‐threonine‐217 were not decreased by suvorexant. Suvorexant decreased amyloid‐β ~10% to 20% compared to placebo starting 5 hours after drug administration.

Interpretation

In this study, suvorexant acutely decreased tau phosphorylation and amyloid‐β concentrations in the central nervous system. Suvorexant is approved by the US Food and Drug Administration to treatment insomnia and may have potential as a repurposed drug for the prevention of Alzheimer's disease, however, future studies with chronic treatment are needed. ANN NEUROL 2023;94:27–40

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMiceAnimalsHumansPhosphorylationtau ProteinsAmyloid beta-PeptidesCentral Nervous SystemOrexin Receptor AntagonistsAzepinesTriazoles

Substanzen

tau ProteinsAmyloid beta-PeptidesOrexin Receptor AntagonistssuvorexantAzepinesTriazoles

Autor:innen und Institutionen

  • Department of Neurology, Washington University School of Medicine, St. Louis, MO.
  • Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, MO.
  • Center on Biological Rhythms and Sleep, Washington University School of Medicine, St. Louis, MO.
  • Biomolecular Analytical Research and Development, MilliporeSigma, St. Louis, MO.

ORCID-Profile: Brendan P Lucey, Vitaliy Ovod

Förderung

  • NIA NIH HHS
  • BrightFocus Foundation
  • National Institute on Aging

Zitieren

APA

Lucey, B. P., Liu, H., Toedebusch, C. D., Freund, D., Redrick, T., Chahin, S. L., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Barthélemy, N. R., & Bateman, R. J. (2023). Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. Annals of Neurology, 94(1), 27-40. https://doi.org/10.1002/ana.26641

Vancouver

Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, et al. Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. Annals of Neurology. 2023;94(1):27-40. doi:10.1002/ana.26641

BibTeX
@article{Lucey2023,
  author = {Lucey, Brendan P and Liu, Haiyan and Toedebusch, Cristina D and Freund, David and Redrick, Tiara and Chahin, Samir L and Mawuenyega, Kwasi G and Bollinger, James G and Ovod, Vitaliy and Barthélemy, Nicolas R and Bateman, Randall J},
  title = {Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {94},
  number = {1},
  pages = {27--40},
  doi = {10.1002/ana.26641}
}
Kostenlos starten →